Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

Next Previous
X
Search
Trial Profile

A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Debio 0123 (Primary)
  • Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Debiopharm

    • Most Recent Events

    • 04 Jun 2024 Results(As of October 24, 2023, n=27 pts) evaluating Safety, pharmacokinetic, and preliminary antitumor activity of Debio 0123 as monotherapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 07 Mar 2024 According to a Debiopharm media release, this studys population is mainly female, burdened by fatal malignancies like Uterine Serous Carcinoma, Epithelial Ovarian Cancer and fallopian tube cancer which are well-known hard-to-treat cancers. Dr. Manish R. Sharma, Principal Investigator at the START Midwest, Michigan.
    • 07 Mar 2024 According to a Debiopharm media release, the first patient dosed in the expansion cohort in this study. Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top